# Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)

> **NCT00106184** · PHASE2 · COMPLETED · sponsor: **University of Pittsburgh** · enrollment: 200 (actual)

## Conditions studied

- Myositis
- Dermatomyositis
- Polymyositis
- Juvenile Dermatomyositis

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00106184
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2010-02
- **Final completion:** 2010-08
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2015-03-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00106184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00106184, "Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00106184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*